This post was originally published on News-medical.net
You will shortly be re-directed to the publisher's website
From 2010 to 2023, GLP-1RAs and SGLT2 inhibitors saw rising prescriptions in type 1 diabetes, particularly for patients with obesity and cardiorenal risks.